Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

PURPOSE: Emerging evidence shows that immune checkpoint inhibitors lead to durable responses in a variety of cancers, including nasopharyngeal carcinoma (NPC), however, combination approaches (i.e., stereotactic body radiation therapy, SBRT) are required to extend this benefit beyond a subset of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jing, Guo, Qiaojuan, Guo, Zengqing, Lu, Tianzhu, Chen, Gang, Lin, Shaojun, Chen, Mei, Chen, Chuanben, Lu, Jianping, Zong, Jingfeng, Tang, Lina, Chen, Yu, Pan, Jianji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254565/
https://www.ncbi.nlm.nih.gov/pubmed/35790987
http://dx.doi.org/10.1186/s13014-022-02073-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254565/
https://www.ncbi.nlm.nih.gov/pubmed/35790987
http://dx.doi.org/10.1186/s13014-022-02073-8

Ejemplares similares